Tag: 3D Signatures

Big News Roundup: Relay Medical To Commence Trading in United States as RYMDF; BriaCell Announces Positive Phase IIa Proof of Concept Data in Advanced Breast Cancer; Initiates Combination Study; Kalytera Announces Progress with Cannabinoid-Based Compound for Treatment of Acute and Chronic Pain

In case you missed it, here is this week's big news roundup in the Life Science sector.

3D Signatures Strengthens Its Intellectual Property With New Patents Issued for Tests in Alzheimer’s Disease, Hodgkin’s Lymphoma and Multiple Myeloma

3D Signatures Inc. (TSXV:DXD,OTCQB:TDSGF), a personalized medicine company with a proprietary software platform (TeloViewTM) based on the three-dimensional analysis of...

Genetics Update: Q1 in Review

With Q1 2018 officially in the books, here the Investing News Network takes a look back at what some of...

3D Signatures Collaborates with MDxHealth to Evaluate Telo-PC™ Test in Prostate Cancer

3D Signatures Inc. (TSXV:DXD,OTCQB:TDSGF) (the “Company” or "3DS"), a personalized medicine company with a proprietary software platform (TeloViewTM) based on...

3D Signatures and l’Institut Universitaire de Cardiologie et de Pneumologie de Québec Announce Collaboration

3D Signatures (TSXV:DXD) a personalized medicine company with a proprietary software platform based on the three-dimensional analysis of chromosomal signatures, is...

3D Signatures Inc. and l’Institut Universitaire de Cardiologie et de Pneumologie de Québec (IUCPQ) Announce Collaboration to Combine TeloView™ with Genome Sequence Analysis in Lung Cancer

3D Signatures Inc. (TSX-V:DXD) (OTCQB:TDSGF) (FSE:3D0) (the "Company" or "3DS"), a personalized medicine company with a proprietary software platform based...

3D Signatures Reports Quarter Ended December 31, 2017 Financial Results

3D Signatures Inc. (TSXV:DXD) (OTCQB:TDSGF) (FSE:3D0) (the "Company" or "3DS"), a personalized medicine company with a proprietary software platform based...